ZoBio is pleased to announce that we have recently taken delivery of our fifth Biacore™ SPR instrument. Biacore 1S+ is one of the first of this newly developed platform to be delivered in Europe and will allow our Assays Group to further expand their leading breadth and depth of methods…
ZoBio Awarded the Company Showing Best Growth Results!
At the recent annual network event organized by Libertatis Ergo Holding BV (LEH) at Leiden Bio Science Park (LBSP) ZoBio was awarded #1 company in the category: Company showing best growth results!
On the premises of LBSP more than 150 biomedical life science companies…
The Upgrade of X-Ray Crystallography Infrastructure Completed
The availability of 3D structural information plays a vital role in modern drug discovery programs. At ZoBio we deeply understand this and have invested heavily in building a team and a lab to create a powerful X-ray crystallography workflow specifically …
Contributing All the Way to the Clinic
Recently the ZoBio team made an important contribution to a drug discovery project for our client Mirati Therapeutics that we are particularly proud of and has had significant impact [1]. This work describes a program to develop inhibitors of the epigenetic target PRMT5 with the potential to …